חזרה לתוצאות החיפוש

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE1, PHASE2

מצבים רפואיים

Small Cell Lung Cancer (SCLC) · Large Cell Neuroendocrine Cancer (LCNEC) · Neuroendocrine Prostate Cancer (NEPC) · Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) · Neuroendocrine Carcinomas (NEC) · Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States

  • USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

  • Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States

  • Yale University Cancer Center, New Haven, Connecticut, United States

  • Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, Maryland, United States

  • Massachusetts General Hospital, Boston, Massachusetts, United States

  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States

  • Washington University School of Medicine (Siteman Cancer Center), St Louis, Missouri, United States

  • University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

  • Duke University Medical Center, Durham, North Carolina, United States

  • Sarah Cannon Research Institute University of Oklahoma, Oklahoma City, Oklahoma, United States

  • Providence Portland Medical Center, Portland, Oregon, United States

  • Mays Cancer Center / University of Texas, San Antonio, San Antonio, Texas, United States

  • NEXT Virginia, Fairfax, Virginia, United States

  • Fred Hutch Cancer Center, Seattle, Washington, United States

צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)